1-4 of 4
Per-Olof Thuresson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Exploring the Impact of Diffuse Large B-Cell Lymphoma (International Prognostic Index [IPI] 2-5) on Clinical and Patient-Relevant Outcomes in the Context of a Clinical Trial

Aino Launonen, Rodrigo Ho, Andrea Knapp, Irene Canales Ruiz, Leonardo Simonella, Per-Olof Thuresson
Journal: Blood
Blood (2021) 138 (Supplement 1): 3577.
https://doi.org/10.1182/blood-2021-146822
Published: 2021
Journal Articles

Comparative Effectiveness of Bendamustine Plus Rituximab (BR) and Rituximab Plus Gemcitabine and Oxaliplatin (R-GemOx) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Felipe Castro, Andy Surinach, MPH, Aino Launonen, Per-Olof Thuresson, Federico Felizzi
Journal: Blood
Blood (2020) 136 (Supplement 1): 41–42.
https://doi.org/10.1182/blood-2020-137529
Published: 2020
Journal Articles

Quality of Life (QoL) in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (NHL) Treated with Polatuzumab Vedotin Plus Rituximab in the ROMULUS Study

Per-Olof Thuresson, MSc, MPharm, Brittany Gentile, PhD, David Ramies, MD, Aino Launonen, MSc, Franck Morschhauser, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4767.
https://doi.org/10.1182/blood-2019-123688
Published: 2019
Journal Articles

Is Obinutuzumab Plus Chemotherapy Followed By Obinutuzumab Monotherapy for Previously Untreated Follicular Lymphoma Patients Cost-Effective in the US?

Gregory F Guzauskas, MSPH, PhD, Anthony Masaquel, MPH, PhD, Per-Olof Thuresson, MSc, Jia Li, PhD, Carolina M Reyes, PhD, David Veenstra, PharmD, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5603.
https://doi.org/10.1182/blood.V130.Suppl_1.5603.5603
Published: 2017